Tonix Pharmaceuticals (TNXP) announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 at the upcoming Vaccine Congress 2025. TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens. Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix’s plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Publishes Study on TNX-1700 Efficacy
- Tonix Pharmaceuticals announces peer-reviewed publication of data on mTNX-1700
- Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes
- Tonix Pharma Presents Data at Rheumatology Congress
- Tonix Pharmaceuticals presented data, analyses of TNX-102 SL treatment effects